Jaap Verweij

688 total citations
10 papers, 587 citations indexed

About

Jaap Verweij is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Jaap Verweij has authored 10 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Pharmacology. Recurrent topics in Jaap Verweij's work include Cancer therapeutics and mechanisms (4 papers), Neutropenia and Cancer Infections (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Jaap Verweij is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Neutropenia and Cancer Infections (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Jaap Verweij collaborates with scholars based in Netherlands, Italy and Germany. Jaap Verweij's co-authors include Alex Sparreboom, Peter de Bruijn, Kees Nooter, Walter J. Loos, G. Stoter, Lia van Zuylen, Eric Brouwer, Gerrit Stoter, Maja J.A. de Jonge and André Planting and has published in prestigious journals such as Analytical Biochemistry, Cancer Chemotherapy and Pharmacology and Anti-Cancer Drugs.

In The Last Decade

Jaap Verweij

10 papers receiving 569 citations

Peers

Countries citing papers authored by Jaap Verweij

Since Specialization

Citations

This map shows the geographic impact of Jaap Verweij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaap Verweij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaap Verweij more than expected).

Fields of papers citing papers by Jaap Verweij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaap Verweij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaap Verweij. The network helps show where Jaap Verweij may publish in the future.

Co-authorship network of co-authors of Jaap Verweij

This figure shows the co-authorship network connecting the top 25 collaborators of Jaap Verweij. A scholar is included among the top collaborators of Jaap Verweij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaap Verweij. Jaap Verweij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism 2001 ·Journal of Chromatography B Biomedical Sciences and Applications ·Peter de Bruijn, Diederik F.S. Kehrer, Jaap Verweij, Alex Sparreboom	21
2	Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles 2001 ·Cancer Chemotherapy and Pharmacology ·Lia van Zuylen, M. O. Karlsson, Jaap Verweij, Eric Brouwer, Peter de Bruijn, Kees Nooter, G. Stoter, Alex Sparreboom	109
3	Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients 2000 ·Anti-Cancer Drugs ·Lia van Zuylen, Luca Gianni, Jaap Verweij, K. Mross, Eric Brouwer, Walter J. Loos, Alex Sparreboom	52
4	Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography 2000 ·Anti-Cancer Drugs ·Walter J. Loos, Peter de Bruijn, Jaap Verweij, Alex Sparreboom	22
5	Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future 1999 ·Investigational New Drugs ·Hans Gelderblom, Maja J.A. de Jonge, Alex Sparreboom, Jaap Verweij	27
6	Determination of Doxorubicin and Doxorubicinol in Plasma of Cancer Patients by High-Performance Liquid Chromatography 1999 ·Analytical Biochemistry ·Peter de Bruijn, Jaap Verweij, Walter J. Loos, (unknown), André Planting, Kees Nooter, Gerrit Stoter, Alex Sparreboom	79
7	Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein 1999 ·Anti-Cancer Drugs ·Alex Sparreboom, André Planting, Roxanne C. Jewell, (unknown), Ate van der Gaast, Peter de Bruijn, Walter J. Loos, Kees Nooter, (unknown), Elaine Paul, Paul Wissel, Jaap Verweij	80
8	Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces 1998 ·Journal of Chromatography B Biomedical Sciences and Applications ·Alex Sparreboom, Peter de Bruijn, Maja J.A. de Jonge, Walter J. Loos, Gerrit Stoter, Jaap Verweij, Kees Nooter	72
9	Quantitation of Cremophor EL in Human Plasma Samples Using a Colorimetric Dye-Binding Microassay 1998 ·Analytical Biochemistry ·Alex Sparreboom, Walter J. Loos, Jaap Verweij, Aad I. de Vos, Maria E.L. van der Burg, G. Stoter, Kees Nooter	48
10	Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection 1997 ·Journal of Chromatography B Biomedical Sciences and Applications ·Peter de Bruijn, Jaap Verweij, Walter J. Loos, Kees Nooter, G. Stoter, Alex Sparreboom	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact